---
title: "Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/003020.SZ.md"
symbol: "003020.SZ"
name: "Hefei Lifeon Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:57:15.145Z"
locales:
  - [en](https://longbridge.com/en/quote/003020.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/003020.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/003020.SZ.md)
---

# Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)

## Company Overview

Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethylphenidate HCL, dioctyl sulfosuccinate sodium salt, and DMSA. It also provides intermediate products, such as sodium paeonolsilate, methy2-(2,3-dichlorobenzylidine)-acetoacetate, 3-mercapto-1-propanol, mercaptosuccinic acid and DMPS monohydrate.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.lifeon.cn](https://www.lifeon.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.55)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 148 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.36% |  |
| Net Profit YoY | -3.70% |  |
| P/B Ratio | 2.22 |  |
| Dividend Ratio | 2.33% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4094284687.46 |  |
| Revenue | 1553427260.64 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 0.00% | D |
| Gross Margin | 65.86% | A |
| Revenue YoY | 0.36% | C |
| Net Profit YoY | -3.70% | C |
| Total Assets YoY | 2.09% | C |
| Net Assets YoY | 1.81% | C |
| Cash Flow Margin | 148.24% | B |
| OCF YoY | 0.36% | C |
| Turnover | 0.00 | E |
| Gearing Ratio | 25.03% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hefei Lifeon Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.36%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-3.70%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.22",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.33%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4094284687.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1553427260.64",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "65.86%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.36%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-3.70%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.09%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.81%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "148.24%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "0.36%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "25.03%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 24.79 | 62/215 | 32.52 | 30.50 | 27.30 |
| PB | 2.18 | 97/215 | 3.07 | 2.81 | 2.53 |
| PS (TTM) | 2.59 | 61/215 | 3.64 | 3.37 | 2.98 |
| Dividend Yield | 2.37% | 54/215 | 2.29% | 2.05% | 1.77% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/003020.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/003020.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/003020.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/003020.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**